BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69:168-76. [PMID: 30878947 DOI: 10.1136/gutjnl-2018-318193] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Kim DW, Kim SY, Kang HJ, Kang JH, Lee SS, Shim JH, Choi SH, Shin YM, Byun JH. Diagnostic performance of ultrasonography-guided core-needle biopsy according to MRI LI-RADS diagnostic categories. Ultrasonography 2021;40:387-97. [PMID: 33472289 DOI: 10.14366/usg.20110] [Reference Citation Analysis]
2 Yan L, Xu F, Dai C. Overexpression of COL24A1 in Hepatocellular Carcinoma Predicts Poor Prognosis: A Study Based on Multiple Databases, Clinical Samples and Cell Lines. Onco Targets Ther 2020;13:2819-32. [PMID: 32308416 DOI: 10.2147/OTT.S247133] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Aitcheson G, Pillai A, Dahman B, John BV. Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Curr Hepatol Rep 2021;:1-11. [PMID: 33552839 DOI: 10.1007/s11901-021-00560-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ye L, Reiter FP, Guba M, De Toni EN. Response to Chen et al. Clin Transl Gastroenterol 2020;11:e00205. [PMID: 32955201 DOI: 10.14309/ctg.0000000000000205] [Reference Citation Analysis]
5 Raffetti E, Portolani N, Molfino S, Mentasti S, Baiocchi GL, Magoni M, Donato F. Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s. Clin Res Hepatol Gastroenterol 2021;45:101433. [PMID: 32409284 DOI: 10.1016/j.clinre.2020.04.004] [Reference Citation Analysis]
6 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
7 Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
8 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Reiter FP, Ye L, Ofner A, Schiergens TS, Ziesch A, Brandl L, Ben Khaled N, Hohenester S, Wimmer R, Artmann R, He Y, Lee SML, Mayr D, Zhang C, Gerbes AL, Mayerle J, Denk G, De Toni EN. p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice. Cell Mol Gastroenterol Hepatol 2021;13:95-112. [PMID: 34537439 DOI: 10.1016/j.jcmgh.2021.09.001] [Reference Citation Analysis]
10 Elfert AY, Salem A, Abdelhamid AM, Salama A, Sourour DA, Shaker O, Keshk M. Implication of miR-122, miR-483, and miR-335 Expression Levels as Potential Signatures in HCV-Related Hepatocellular Carcinoma (HCC) in Egyptian Patients. Front Mol Biosci 2022;9:864839. [DOI: 10.3389/fmolb.2022.864839] [Reference Citation Analysis]
11 Hua S, Quan Y, Zhan M, Liao H, Li Y, Lu L. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1. Cancer Cell Int 2019;19:203. [PMID: 31384178 DOI: 10.1186/s12935-019-0919-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
12 Sun X, Hu D, Zhang Y, Lyu N, Xu L, Chen Q, Lai J, Chen M, Zhao M. Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients? J Hepatocell Carcinoma 2020;7:377-84. [PMID: 33365285 DOI: 10.2147/JHC.S287641] [Reference Citation Analysis]
13 De Toni EN. Immune checkpoint inhibitors: use them early, combined and instead of TACE? Gut 2020;69:1887-8. [PMID: 31611301 DOI: 10.1136/gutjnl-2019-319658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kim DH, Hong SB, Choi SH, Kim SY, Shim JH, Lee JS, Choi JI, Kim S. Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis. Gut 2021:gutjnl-2020-323615. [PMID: 33649047 DOI: 10.1136/gutjnl-2020-323615] [Reference Citation Analysis]
15 Schütte K, Schinner R, Fabritius MP, Möller M, Kuhl C, Iezzi R, Öcal O, Pech M, Peynircioglu B, Seidensticker M, Sharma R, Palmer D, Bronowicki JP, Reimer P, Malfertheiner P, Ricke J. Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. Liver Cancer 2020;9:771-86. [PMID: 33442545 DOI: 10.1159/000510798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhan J, Wu Y, Wang H, Liu J, Ma Q, Xiao K, Li Z, Li J, Luo F, Tan H. An injectable hydrogel with pH-sensitive and self-healing properties based on 4armPEGDA and N-carboxyethyl chitosan for local treatment of hepatocellular carcinoma. Int J Biol Macromol 2020;163:1208-22. [PMID: 32645496 DOI: 10.1016/j.ijbiomac.2020.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
17 Ye L, Kriegl L, Reiter FP, Munker SM, Itzel T, Teufel A, Ziesch A, Török HP, Kirchner T, Gerbes AL, Guba M, Mayerle J, De Toni EN. Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00124. [PMID: 31990698 DOI: 10.14309/ctg.0000000000000124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, Ju Z, Rao J, Lu L. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med 2020;9:8159-72. [PMID: 32977361 DOI: 10.1002/cam4.3411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Ye L, Zhang C, Seidensticker M, Mayerle J, Reiter FP, De Toni EN. Durable Complete Response of Brain Metastasis From Hepatocellular Carcinoma On Treatment With Nivolumab and Radiation Treatment. Am J Gastroenterol 2020;115:2114-6. [PMID: 32852335 DOI: 10.14309/ajg.0000000000000800] [Reference Citation Analysis]
20 Verma M, Paik JM, Younossi I, Tan D, Abdelaal H, Younossi ZM. The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. Cancer Med 2021;10:6273-81. [PMID: 34405568 DOI: 10.1002/cam4.4166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 2021;6:128. [PMID: 33776057 DOI: 10.1038/s41392-021-00507-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
22 De Toni EN, Roessler D. Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. Gut 2020;69:2056.1-2058. [DOI: 10.1136/gutjnl-2020-320604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Sun LY, Ouyang Q, Cen WJ, Wang F, Tang WT, Shao JY. A Model Based on Artificial Intelligence Algorithm for Monitoring Recurrence of HCC after Hepatectomy. Am Surg 2021;:31348211063549. [PMID: 34894786 DOI: 10.1177/00031348211063549] [Reference Citation Analysis]
24 Walter F, Fuchs F, Gerum S, Rottler MC, Erdelkamp R, Neumann J, Nierer L, Guba M, De Toni EN, Seidensticker M, Ricke J, Belka C, Corradini S. HDR Brachytherapy and SBRT as Bridging Therapy to Liver Transplantation in HCC Patients: A Single-Center Experience. Front Oncol 2021;11:717792. [PMID: 34513694 DOI: 10.3389/fonc.2021.717792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Khaled NB, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken PA, Lange CM, Wege H, Kandulski A, Dechêne A, Venerito M, Berres ML, Luedde T, Kubisch I, Reiter FP, De Toni EN. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol 2022. [PMID: 35081747 DOI: 10.2217/fon-2021-1261] [Reference Citation Analysis]
26 An J, Kim HI, Oh B, Oh YJ, Oh JH, Kim W, Sung CO, Shim JH. Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study. Gut 2021:gutjnl-2021-325844. [PMID: 34493591 DOI: 10.1136/gutjnl-2021-325844] [Reference Citation Analysis]
27 Kang D, Shim S, Cho J, Lim HK. Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018. Korean J Radiol 2020;21:633-46. [PMID: 32410403 DOI: 10.3348/kjr.2019.0808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021;12:2933-51. [PMID: 33854594 DOI: 10.7150/jca.52187] [Reference Citation Analysis]
29 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Reference Citation Analysis]
30 Huang B, Zhang B, Liang B, Fang L, Ye X. Ultra-low level detection of hepatocellular carcinoma global methylation using a AuNP modified carbon fiber microelectrode. RSC Adv 2020;10:16277-83. [DOI: 10.1039/d0ra00905a] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, Lee SS, Shin YM, Won HJ, Kim P. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut 2019;68:1719-21. [DOI: 10.1136/gutjnl-2019-318555] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
32 Tan LLY, Chew VTW, Syn N, Tan EK, Koh YX, Teo JY, Cheow PC, Jeyaraj PR, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ, Goh BKP. Effect of age on the short- and long-term outcomes of patients undergoing curative liver resection for HCC. Eur J Surg Oncol 2021:S0748-7983(21)00999-9. [PMID: 34972621 DOI: 10.1016/j.ejso.2021.12.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Zhang N, Jiang W, Zhang Y, Song TQ, Lv J, Gu J, Wu Y, Qian J, Tian D, Guo Q, Zhang L, Sun J, Xie Y, Wang Z, Sun X, Yan Z, Zhou Y, Liu J, Qiu Y, Yang B, Shen Z, Lu W. Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria. Gut 2020;69:1893-5. [PMID: 31748202 DOI: 10.1136/gutjnl-2019-320073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Fu X, Li X, Han D, Yang W, Liu C, Fan L, Ding S, Ma Y. Ultrasensitive electrochemical biosensor for des-gamma-carboxy prothrombin analysis based on core-shell Pd@PtCu-alloy loaded on WS2 nanosheet. Journal of Electroanalytical Chemistry 2021;888:115213. [DOI: 10.1016/j.jelechem.2021.115213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. Am J Gastroenterol 2020;115:1642-9. [PMID: 32530829 DOI: 10.14309/ajg.0000000000000715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]